Stoke Therapeutics, Inc. (STOK) stock
STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30178% above fair value
$26.41−0.22 (-0.83%)
Close on Nov 17, 2026Market cap $1.70BP/E –Yield –
Stoke Therapeutics cash
Cash and short-term investments held at the end of each period.
Stoke Therapeutics's cash was $292.82M at Jun 30, 2026. For fiscal 2025 it was $284.67M, up 31.2% from the year before. The highest annual figure on record is $287.31M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $284.67M | +31.2% |
| FY2024 | Dec 31, 2024 | $216.90M | +7.7% |
| FY2023 | Dec 31, 2023 | $201.39M | -12.3% |
| FY2022 | Dec 31, 2022 | $229.60M | +4.5% |
| FY2021 | Dec 31, 2021 | $219.81M | -23.5% |
| FY2020 | Dec 31, 2020 | $287.31M | +29.1% |
| FY2019 | Dec 31, 2019 | $222.47M | +111.1% |
| FY2018 | Dec 31, 2018 | $105.40M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $292.82M | +18.2% |
| Q1 FY2026 | Mar 31, 2026 | $343.55M | -3.9% |
| Q4 FY2025 | Dec 31, 2025 | $284.67M | +31.2% |
| Q3 FY2025 | Sep 30, 2025 | $248.31M | +3.8% |
| Q2 FY2025 | Jun 30, 2025 | $247.71M | -12.2% |
| Q1 FY2025 | Mar 31, 2025 | $357.32M | +100.1% |
| Q4 FY2024 | Dec 31, 2024 | $216.90M | +7.7% |
| Q3 FY2024 | Sep 30, 2024 | $239.20M | +11.4% |
| Q2 FY2024 | Jun 30, 2024 | $281.98M | +21.8% |
| Q1 FY2024 | Mar 31, 2024 | $178.58M | -29.6% |
| Q4 FY2023 | Dec 31, 2023 | $201.39M | -12.3% |
| Q3 FY2023 | Sep 30, 2023 | $214.72M | -14.7% |
| Q2 FY2023 | Jun 30, 2023 | $231.45M | -16.0% |
| Q1 FY2023 | Mar 31, 2023 | $253.67M | -13.5% |
| Q4 FY2022 | Dec 31, 2022 | $229.60M | +4.5% |
| Q3 FY2022 | Sep 30, 2022 | $251.66M | +6.6% |
| Q2 FY2022 | Jun 30, 2022 | $275.63M | +9.7% |
| Q1 FY2022 | Mar 31, 2022 | $293.22M | +9.6% |
| Q4 FY2021 | Dec 31, 2021 | $219.81M | -23.5% |
| Q3 FY2021 | Sep 30, 2021 | $236.16M | +23.3% |
| Q2 FY2021 | Jun 30, 2021 | $251.23M | +24.4% |
| Q1 FY2021 | Mar 31, 2021 | $267.51M | +26.6% |
| Q4 FY2020 | Dec 31, 2020 | $287.31M | +29.1% |
| Q3 FY2020 | Sep 30, 2020 | $191.46M | -17.8% |
| Q2 FY2020 | Jun 30, 2020 | $201.93M | -16.8% |
| Q1 FY2020 | Mar 31, 2020 | $211.29M | +114.2% |
| Q4 FY2019 | Dec 31, 2019 | $222.47M | +111.1% |
| Q3 FY2019 | Sep 30, 2019 | $233.05M | +1103.3% |
| Q2 FY2019 | Jun 30, 2019 | $242.68M | +2442.2% |
| Q1 FY2019 | Mar 31, 2019 | $98.65M | – |
| Q4 FY2018 | Dec 31, 2018 | $105.40M | – |
| Q3 FY2018 | Sep 30, 2018 | $19.37M | – |
| Q2 FY2018 | Jun 30, 2018 | $9.55M | – |
See a number that looks wrong?